Ocular Therapeutix (OCUL) Return on Sales (2014 - 2026)

Ocular Therapeutix's Return on Sales history runs 13 years deep, the most recent figure standing at 0.08% for Q1 2026.

• On a quarterly basis, Return on Sales fell 2.0% year-over-year to 0.08% in Q1 2026; TTM through Mar 2026 was 0.06%, a 2.0% decrease from a year earlier, with the FY2025 full-year figure at 0.1%, down 5.0% from the prior year.
• Return on Sales eased to 0.08% in Q1 2026 per OCUL's latest filing, from 0.05% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q4 2022 and bottomed at 0.08% in Q1 2026.
• The 5-year median for Return on Sales is 0.02% (2024), against an average of 0.03%.
• Across the five-year window, Return on Sales climbed 2 bps in 2022 and decreased 3 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2022, then plunged by 58 bps to 0.02% in 2023, then slumped by 57 bps to 0.03% in 2024, then plunged by 77 bps to 0.05% in 2025, then sank by 64 bps to 0.08% in 2026.
• Per Business Quant, the three latest OCUL Return on Sales figures stand at 0.08% (Q1 2026), 0.05% (Q4 2025), and 0.05% (Q3 2025).